Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultralow Dose PET Imaging for Amyloid Detection
NCT07012993Phase 2Recruiting
- Sponsor
- Akiva Mintz
- Start
- May 2025
- Primary completion
- Jun 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Florbetapir and flutemetamol in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and Dementia, sponsored by Akiva Mintz. Primary endpoints: Signal-to-Noise Ratio at 1 year, Contrast-to-Noise Ratio at 1 year and 5 more. Started May 2025; status: recruiting.
02
Drugs
Florbetapirflutemetamol
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)Dementia
Beyond the preview
Go deeper on NCT07012993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07012993.